FDC reported a consolidated net profit of ₹132 crore for the quarter ended June 30, 2026, marking a 9.2% increase from ₹121 crore in the corresponding period of the previous year. Revenue from operations grew to ₹668 crore, up 3.0% year-on-year, driven primarily by a robust 118.4% surge in its International Formulations business in the United States. This growth offset a 1.9% decline in Domestic Formulations and a 2.9% dip in API sales, highlighting a shifting revenue mix towards high-growth export markets.

The financial results were reviewed by statutory auditors B S R & Co. LLP and approved by the Board on August 5, 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Basic and diluted earnings per share (EPS) rose to ₹8.14, compared to ₹7.45 in Q1FY26. The company also secured U.S. FDA approval for Cefixime for Oral Suspension USP 100mg/5mL and 200mg/5mL during the quarter, strengthening its pipeline in the regulated market.

Financial Performance Highlights

FDC’s top-line growth was accompanied by a slight contraction in EBITDA margins, indicating cost management challenges amidst rising input expenses. Consolidated EBITDA increased to ₹143 crore, up 1.9% from ₹140 crore in Q1FY26, but the margin compressed to 21.4% from 21.6%. Profit before tax (PBT) rose 9.4% to ₹175 crore. Finance costs remained low at ₹83 million (consolidated), showing effective debt management.

On a standalone basis, revenue from operations was ₹655.1 crore, up from ₹642.3 crore year-on-year. Other income contributed significantly to total income, while standalone net profit stood at ₹132.02 crore, compared to ₹122.20 crore in Q1FY25.

Segment-Wise Performance

The divergence in segment performance underscores FDC’s strategic pivot towards international markets. Domestic Formulations, which accounted for approximately 85% of consolidated sales, declined 1.9% to ₹569 crore due to subdued performance in key brands like Zifi, Enerzal, and Simyl MCT. However, secondary sales data from IQVIA showed a 9.0% growth for the quarter ended June 30, 2026, suggesting potential channel inventory buildup.

International Formulations emerged as the primary growth engine, contributing ₹73 crore (11% of total sales) with a 74.2% YoY growth. The US business alone delivered ₹34 crore, up 118.4%, while Non-US exports grew 47.7% to ₹39 crore. Conversely, the API segment recorded a 2.9% decline to ₹24 crore, accounting for only 4% of consolidated sales.

Analytical Observations

While revenue growth remains robust, the divergence between revenue growth (3.0%) and profit growth (9.2%) suggests operational leverage or favorable mix shifts towards higher-margin international products. However, the marginal decline in EBITDA margins warrants monitoring as input costs remain volatile. The company continues to monitor regulatory changes impacting employee benefit obligations, having recognized a non-recurring exceptional item of ₹2,079 million in FY26 due to actuarial valuation changes under Ind AS 19. No such impact was recorded in Q1FY26.

Auditor’s Note

B S R & Co. LLP, the statutory auditors, issued an unmodified review conclusion on both standalone and consolidated results. The audit report highlights that quarterly figures may not be directly additive to year-to-date numbers due to fair value adjustments recognized under Ind AS 109. Additionally, interim financial information from three wholly-owned subsidiaries—FDC International Limited (UK), FDC Inc. (USA), and Fair Deal Corporation Pharmaceuticals SA (South Africa)—was not reviewed but deemed immaterial to the group.

Food Safety Officials from the Food & Drug Administration (FDA), Maharashtra, visited FDC Limited depots in Chhatrapati Sambhaji Nagar and Nagpur on June 3, 2026, seizing certain stock of the company's product 'Enerzal' and collecting samples for examination regarding alleged misbranding. The company stated that the final examination order is pending and it will take appropriate legal recourse, while business operations continue as usual.

Regulatory Action

The FDA's action involves the seizure of stock and the collection of samples for examination. According to the disclosure, the inspection relates to the alleged misbranding of the product. The company received the communication regarding this action on June 3, 2026. As of the filing date, the final examination order is yet to be received.

Company Response

FDC Limited stated that there is no material financial impact on the company or its operations as of the current date. The company has indicated its intent to pursue appropriate legal recourse in response to the regulatory action. Stakeholders are advised to await further official communication regarding the outcome of the examination.